Highwise Health
U.S.

Paliperidone Study Proposed New Dosing Schedules

Researchers modeled whether higher doses of a schizophrenia medication could safely extend the time between treatments.

Updated on Sept. 23, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a glass medical vial and syringe, symbolizing clinical research into medication dosing intervals.
Researchers modeling alternative dosing intervals for paliperidone palmitate found that higher doses might allow for longer periods between maintenance treatments. AI Illustration. Upload story photo >

Live Poll

Do you believe alternative dosing research effectively improves long-term medication adherence for psychiatric patients?

A new study published in The Journal of Clinical Psychiatry suggests that alternative maintenance dosing intervals for the schizophrenia medication paliperidone palmitate may be possible. The findings could eventually offer more flexibility for patients managing the condition.

Why it matters

Schizophrenia management often faces challenges with medication adherence, and extending the time between doses could improve treatment accessibility. This research explores whether higher maintenance doses might maintain drug levels effectively over longer periods.

Using data from two Phase 1 clinical studies, researchers utilized pharmacokinetic modeling to simulate steady-state paliperidone exposure. While the study found potential equivalency for specific intervals, the findings remain strictly preliminary without clinical validation.

The players

ERZOFRI

A medication approved by the FDA for the treatment of schizophrenia.

The Journal of Clinical Psychiatry

A peer-reviewed medical publication covering developments in mental health research.

The details

The analysis suggests that a 351 mg dose administered every four or six weeks could theoretically match the steady-state exposure provided by the current standard of 234 mg given every three or four weeks, respectively. By increasing the total amount of medication per injection, the modeling aimed to compensate for longer gaps between doses. These projections are based on simulation methods rather than direct observations of drug effects in clinical populations.

Timeline

  1. 2024: ERZOFRI received FDA approval.

  2. April 2025: ERZOFRI became available in the United States.

  3. September 2026: Study published in The Journal of Clinical Psychiatry.

Health Landscape

The study sits within the ongoing effort to optimize long-acting injectable antipsychotics to address the complex needs of those with schizophrenia. It marks a shift from existing maintenance protocols by testing the limits of pharmacokinetic simulation to suggest potential future dosing flexibility.

These findings are based on computer modeling and are not a substitute for currently approved treatment plans. Any questions about medication timing or dosage adjustments should always be directed to your prescribing physician to ensure safe and appropriate care.

The takeaway

While pharmacological modeling offers a promising glimpse into more flexible dosing schedules, these findings are preliminary and currently lack clinical verification. Patients should continue to follow their current prescribed treatment schedule and discuss any concerns about adherence with their doctor.

Further reading

For more on managing long-term treatment strategies, explore the Alzheimer’s section of our site.

More information

Review the ERZOFRI full prescribing information for clinical details and approved usage guidelines.

Source note: This article includes information reported by Firstwordpharma.

Live Poll

Do you believe alternative dosing research effectively improves long-term medication adherence for psychiatric patients?